Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
暂无分享，去创建一个
A. Lugovskoy | G. Farrington | J. Browning | Xiufeng Wu | F. Huang | S. Demarest | V. Bailly | J. Michaelson | E. Garber | I. Joseph | Sharon X Gao | B. Miller | W. Snyder | S. Glaser | Adam Doern | A. Amatucci | Xin Wang | S. Phan